Takeda Pharmaceutical Company
↗Tokyo, Japan
Takeda Pharmaceutical Company Limited is a multinational pharmaceutical company headquartered in Tokyo, Japan, founded in 1781. As a top-20 global pharmaceutical company and the third-largest in Asia, Takeda operates across six continents with over 47,000 employees. The company is focused on advancing science to deliver life-enhancing medicines, with primary therapeutic areas including oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies, and vaccines. Following the 2019 acquisition of Shire for $62 billion, Takeda transformed into a global, R&D-driven biopharmaceutical leader with significant capabilities in rare genetic disorders and immunology. The company maintains robust R&D operations with global research centers in Cambridge (Massachusetts), San Diego (California), and Shonan (Japan), employing approximately 20,000+ employees in the United States across 39 states.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Big Pharma - Global Innovator
SIZE & FINANCIALS
Employees:10000+
Revenue:$28-31B
Founded:1781
Ownership:public
Status:operating
STOCK
Exchange:NYSE, Tokyo Stock Exchange
Ticker:TAK (NYSE), 4502 (Tokyo)
Market Cap:$47-52B
PIPELINE
Stage:Phase 3
Lead Drug Stage:Phase 3 (multiple assets)
Modalities:Small molecule, mAb, ADC, Biologics, Plasma-derived, Vaccines
Trial Phases:Phase 3: 6
CORPORATE STRUCTURE
Subsidiaries:Shire (acquired 2019)
Key Partnerships:Innovent Biologics - oncology collaboration (IBI363, IBI343), Xoma - expansion agreement for 9 new assets, Protagonist Therapeutics - rusfertide co-development, International Medical Corps, Society of Critical Care Medicine, UNOPS Bangladesh, Vitamin Angels - CSR partnerships
COMPETITION
Position:Leader
Competitors:Merck, AbbVie, Bristol Myers Squibb, Kite Pharma, Moderna, Horizon Therapeutics, Incyte, Jazz Pharmaceuticals
LEADERSHIP
Key Executives:
Christophe Weber - President, CEO & Representative Director
Julie Kim - President, U.S. Business Unit (current); CEO-Designate
Milano Furuta - Director, Chief Financial Officer
Andrew Plump - Director, President of R&D
Scientific Founders:Iemon Takeda (1781)
Board Members:Masami Iijima (External Director, Chair), Ian Clark (External Director), Steven Gillis (External Director), Emiko Higashi (External Director), John Maraganore (External Director), Michel Orsinger (External Director), Miki Tsusaka (External Director)
LINKS
Website:takeda.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Takeda Pharmaceutical Company. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.